GSK GSK plc Total Debt to Capital

GSK plc relies on a powerful staff of scientists and strict ethical standards in R&D. The total debt-to-equity ratio objectively records financial stability, where the value of 0.97 characterizes this level. Revenues are based on global supplies of vaccines and HIV therapies, while the defensive qualities of the healthcare sector protect profits from market downturns.

GSK GSK Corp All Debt to Shareholders' Equity Ratio (07/04/2022 - 10/28/2026)

Analytical breakdowns for GSK plc

- price and consensus price forecast:

Stock Price GlaxoSmithKline plc|GSK - Fair Value Consensus

- market capitalization data:

Market Capitalization GSK|GSK - Enterprise Value

- book capitalization data:

Net Assets per Single Share GSK|GSK - Accounting Value of Company|Market Value to Book Value Ratio gsk.com|GSK - Cumulative Company Assets

- debt and liquidity data:

Basic company analysis:GSK - GSK plc

The leverage ratio determines a business's dependence on borrowed capital relative to its own equity. This metric measures the volume of debt obligations per unit of shareholder equity, reflecting financial stability. By analyzing the current total debt leverage level, an investor assesses the risk of default amid rising interest rates. For GSK plc (GSK), this balance is critical due to vaccine development costs. High indebtedness will increase pressure in the event of legal costs related to Zantac.

Key competitors